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PERSPECTIVE
Adult pulmonary tuberculosis as a 




The intricate relationship between tuberculosis (TB) and immune system remains poorly understood. It is generally 
believed that weakening of the immune response against Mycobacterium tuberculosis leads to reactivation of latent 
infection into the active pulmonary disease. However, heterogeneous nature of TB and failure of rationally designed 
vaccines in clinical trials raises serious questions against the simplistic view of TB as an outcome of weakened immu-
nity. In the wake of accumulating human TB data, it is argued here that a hyperactive antimycobacterial immune 
response is to blame for the pathogenesis of pulmonary TB in immunocompetent adults. Direct and indirect evidence 
supporting this notion is presented in this article. Revisiting the role of immune system in TB pathogenesis will pave 
the way for effective anti-TB vaccines.
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Background
Tuberculosis (TB) continues to be one of major global 
health threats resulting in nearly 1.5 million deaths per 
year [1]. An effective vaccine is urgently required to con-
trol current specter of TB, but the development of new 
TB vaccines has been hampered due to poor understand-
ing of the intricate relationship between TB and immune 
system. It is commonly believed that weakening of the 
immune system leads to reactivation of latent Mycobacte-
rium tuberculosis (Mtb) infection into the active pulmo-
nary disease. Although a major support to this notion is 
provided by the significantly elevated risk of TB in immu-
nocompromised hosts (such as those suffering from HIV/
AIDS), TB in immunocompromised people is different 
from that occurring in immunocompetent adults.
In immunocompetent adults, TB occurs as a post-pri-
mary and localized disease affecting mainly lung tissue. 
On the contrary, Mtb infection in immunocompromised 
hosts leads to a primary progressive disease, commonly 
affecting extrapulmonary sites and often occurring in a 
severe form. Owing to its heterogeneous presentation and 
pattern of occurrence, an increasing number of research-
ers have been questioning the simplistic view of TB as 
an outcome of weakened immune response. Failure of 
rationally designed vaccines, e.g. MVA85A (modified vac-
cinia virus Ankara expressing Mtb antigen  85A), which 
had been aimed at boosting antimycobacterial immune 
response, further raises the serious concerns about our 
current understanding of the TB immunobiology.
On the other hand, a number of experimental and 
observational studies have shown that a heightened 
immune response is closely associated with active pul-
monary TB or its elevated risk in immunocompetent 
adults. Based on these and other findings, it is proposed 
here that a hyperactive antimycobacterial immune 
response is to blame for the pathogenesis of adult pulmo-
nary TB in immunocompetent hosts. Direct and indirect 
evidence supporting this notion is presented in this man-
uscript. Protective immunity in TB is briefly described in 
the beginning, which is followed by the findings favoring 
the pathological role of hyperactive immune response in 
adult pulmonary TB. Finally, heterogeneity of TB and its 
role in complicating TB immunobiology has been dis-
cussed in short.
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Protective immune response against Mtb
The immune response to Mtb begins with inhalation of 
bacilli-laden droplets, produced by an active TB patient 
while coughing. Inside lungs, Mtb is recognized and 
phagocytosed by resident macrophages. These cells 
respond to Mtb infection by producing proinflammatory 
cytokines and chemokines, reactive nitrogen/oxygen spe-
cies and antimicrobial peptides [2]. Monocytes extrava-
sate into infected tissue, and under the influence of 
locally present cytokines and growth factors, mature into 
macrophages and dendritic cells (DCs) [3]. After migrat-
ing to the draining lymph nodes, infected and antigen-
loaded DCs mount Mtb-specific CD4+ and CD8+ T cell 
responses.
CD4+ T lymphocytes are the key orchestrators of 
protective immunity against Mtb [2]. The critical role 
of these cells in protection against Mtb is evidenced by 
CD4+ T cell-lymphopenic HIV-infected people, who 
have 20–35 times higher risk of TB, compared with 
uninfected individuals [4]. CD4+ T cells act primarily 
by activating macrophages through soluble factors like 
IFN-gamma and TNF-alpha, and cell surface molecules 
such as CD40 [2]. Activated macrophages are capable of 
restricting Mtb growth and killing the intracellular bacilli 
in an inducible nitric oxide synthase (iNOS)-dependent 
manner. Activated macrophages have also been shown to 
enforce phagolysosomal fusion, which is otherwise inhib-
ited by the pathogenic mycobacteria.
Proinflammatory cytokines TNF-alpha and IFN-gamma 
are the important mediators of protective immunity 
against Mtb [5]. TNF-alpha is produced mainly by mac-
rophages, neutrophils, DCs and T cells. It activates mac-
rophages and induces chemokine secretion by them, 
resulting in recruitment of other cells to the site of infec-
tion [6]. Further, apoptosis of Mtb-infected macrophages 
is enhanced in the presence of TNF-alpha, leading to the 
elimination of intracellular Mtb [7]. TNF-alpha has also 
been suggested to play a role in the granuloma forma-
tion and maintenance [8]. The importance of TNF-alpha 
in protection against Mtb is highlighted by reactivation 
of latent infection in people (such as rheumatoid arthritis 
patients), who have been treated with anti-TNF agents [9].
In Mtb-infected hosts, IFN-gamma is mainly produced 
by CD4+ T cells, although CD8+ T cells, γδT cells, NK 
cells and NKT cells also contribute towards it [10]. Pro-
duction of IFN-gamma is largely dependent on IL-12, 
which is secreted by Mtb-infected DCs and macrophages. 
Mutations in IL-12/IFN-gamma axis predispose the 
affected individuals to progressive mycobacterial infection 
[11]. A partial loss of IFN-gamma receptor I (IFNGR1) 
enhances susceptibility to disseminated disease with BCG 
and environmental mycobacteria, whereas complete loss 
of IFNGR1 has been shown to result in earlier onset of 
disease symptoms [12]. Similarly, children with IL-12 
receptor β1 (IL-12Rβ1) deficiency have been shown to 
develop the severe form of TB, frequently [13].
The coordinated response of innate and adaptive 
immune systems against Mtb results in the well-organ-
ized cellular fortress, which can effectively shield healthy 
lung tissue from Mtb. This fortress, referred to as granu-
loma, has infected macrophages, neutrophils, giant cells 
and epithelioid cells in its core, which is surrounded 
by CD4+ T cells, CD8+ T cells, B cells, and fibroblasts 
[14]. Granuloma provides a special framework, wherein 
infected macrophages remain sequestered from healthy 
tissue, while maintaining the close contact with effector 
T cells [15]. Most of the latently infected people with Mtb 
residing in their granulomas do not develop active dis-
ease and remain healthy lifelong, illustrating the protec-
tive role of granulomas against Mtb.
Hyperactive immune response as an etiologic 
agent in adult pulmonary TB
Like any other thing in excess, the excessive immune 
response is not good for health and it holds true for the 
antimycobacterial immune response as well. Studies have 
shown that most of the adults pulmonary TB patients 
are not immunodeficient and are not susceptible to 
other infectious diseases in general. On the other hand, 
a number of evidence shows that a hyperactive anti-Mtb 
immune response, characterized by excessive CD4+ T 
cell activity and IFN-gamma levels, is to blame for the 
pathogenesis of adult pulmonary TB in immunocompe-
tent hosts. This evidence is presented below.
Lessons from tuberculin skin test
Tuberculin skin test (TST) is a widely used assay to 
diagnose exposure to Mtb. It involves the intradermal 
injection of purified protein derivative (PPD) and moni-
toring for a delayed-type hypersensitivity (DTH) reac-
tion, which is seen as the local skin induration (tuberculin 
reaction) [16]. DTH is a cellular immune response, pri-
marily involving CD4+ T cells and macrophages, against 
an antigen (or antigens) to which an individual is prior 
sensitized. The occurrence of an intense DTH reaction 
in adult pulmonary TB patients, as demonstrated by the 
large area of induration, shows that these individuals 
mount and maintain the higher levels of cellular immune 
responses to Mtb antigens [17].
Studies on the close contacts of TB patients have 
shown that those who initially exhibited a greater sen-
sitivity to tuberculin carry the higher risk of develop-
ing active TB [18]. Accordingly, an intense tuberculin 
reaction is considered as more serious, and more likely 
indicate that a person is suffering from active disease or 
is about to develop it [19]. On the other hand, latently 
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infected people exhibit a relatively lower sensitivity 
to Mtb antigens, indicating that a moderate anti-Mtb 
immune response is able to confer protection against 
active disease [20].
It should be noted that even though the intensity of 
tuberculin reaction correlates with the risk of pulmonary 
TB, lack of reactivity or anergy to Mtb antigens is not an 
indicative of resistance to the disease [21]. Anergy to Mtb 
antigens can be observed in patients suffering from HIV/
AIDS or other forms of immunodeficiencies, but its under-
lying mechanisms in every subset of patients are not well-
understood [22]. As anergy to Mtb antigens signifies the 
lack of TH1 type of antimycobacterial immune response, 
it can be associated with the unrestricted growth of the 
bacilli in any tissue/organ and the increased risk of mortal-
ity [21]. Nevertheless, the occurrence of intense tuberculin 
reaction in adult pulmonary TB patients demonstrates a 
strong association between heightened antimycobacterial 
immune response and the active disease.
Immune profiling of latent and active TB patients
The antimycobacterial immune response has been char-
acterized in latent and active TB patients with an aim 
to understand underlying mechanisms of TB pathogen-
esis. These studies have shown that heightened levels of 
IFN-gamma are most invariably observed in lung tissue, 
bronchoalveolar lavage (BAL) fluid, pleural effusion, and 
lymph nodes of active TB patients [5]. Interestingly, BAL 
fluid IFN-gamma levels of active TB patients directly cor-
relate with disease severity and subside with successful 
chemotherapy [23]. Few studies have also demonstrated 
enhanced levels of IFN-gamma in blood-plasma of active 
TB patients, compared with healthy controls [24]. Similar 
to findings in human patients, increased IFN-gamma lev-
els have also been observed in M. bovis-infected calves, 
which are natural hosts of these bacilli [25]. IFN-gamma 
secretion by M. bovis-specific T cells from these animals 
was also found to correlate with disease severity.
The above findings are further corroborated by tran-
scriptional profiling of immune response in active TB 
patients. Microarray analysis of whole blood cells by 
Berry et  al. has revealed an increased transcription of 
IFN-gamma- and type I IFN-inducible genes in active 
TB patients, compared with latently infected people and 
healthy controls [26]. Although, the occurrence of type 
I IFN-inducible transcriptomic signature in active TB 
patients was a surprising finding, the presence of IFN-
gamma-inducible signature correlated with the height-
ened IFN-gamma levels in these people. Interestingly, 
as in the case of IFN-gamma levels in different tissues, 
IFN-inducible transcriptomic signature was also found to 
correlate with disease severity and subsided with success-
ful chemotherapy. An interesting observation in these 
studies was that IFN-inducible transcriptomic signature 
was absent from most, but 10–20  % of latently infected 
people, who might be representing the transition state 
between latent and active TB [26]. Resolution of microar-
ray data to cellular level showed that IFN-inducible genes 
in active TB patients were predominantly expressed in 
neutrophils, and to some extent in monocytes [26]. The 
presence of heightened IFN-gamma levels and its induc-
ible transcriptomic signature in TB patients corroborated 
an association between hyperactive immune response 
and the active pulmonary disease.
Course of Mtb infection in immunocompetent adults
Mtb infection in otherwise healthy immunocompe-
tent adults follows a definite pattern. Initial exposure 
to Mtb in these people is followed by an asymptomatic 
phase of infection called latent TB (LTB) [2]. Although 
most immunocompetent adults with LTB would remain 
healthy, 5–10  % of them are destined to develop active 
disease in their lifetime. The risk of developing the active 
disease is maximum within 1–2  years post-infection 
and declines thereafter [18, 27]. There is almost always 
a time lag between Mtb exposure and active disease in 
immunocompetent adults, which probably represents 
the time period required for host antimycobacterial 
immune response to accumulating and reach pathologi-
cal intensity.
A peculiar feature of adult pulmonary TB is that peo-
ple who have been cured of active disease do not develop 
a resistance to subsequent infection. Instead, it has been 
observed that these people carry a significantly elevated 
risk of developing active disease with Mtb re-exposure 
[28]. This aspect of TB, although unexplained so far, 
supports the pathological role of immune response in 
the  adult pulmonary disease. In fact, Mtb-specific lym-
phocytes have been found to persist as memory cells for 
an extended period of time after successful chemother-
apy [24, 29]. Re-stimulation of these memory cells with 
Mtb antigens is bound to result in a rapid and fully blown 
antimycobacterial immune response. If the weakened 
immune response were responsible for the pathogen-
esis of adult pulmonary TB, activation of memory cells 
would have conferred protection against active disease. 
However, pulmonary TB in immunocompetent adults 
being a manifestation of the hyperactive antimycobacte-
rial immune response, cured TB patients are doomed to 
suffer again.
Immune reconstitution‑induced TB (IR‑TB) in HIV/AIDS 
patients
HIV/AIDS, which is characterized by reduced levels of 
CD4+ T cells, offers a unique opportunity to understand 
the role of immune system in TB pathogenesis. It allows 
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us to examine the effect of a weakened as well as a height-
ened immune response on the outcome of mycobacterial 
infection. Three possible outcomes of Mtb co-infection 
in HIV/AIDS patients are: (i) progressive primary TB (ii) 
progressive latent TB and (iii) immune reconstitution-
induced TB (IR-TB).
Given the central importance of CD4+ T cells in con-
taining Mtb infection, the occurrence of a progressive 
primary TB in HIV/AIDS patients is conceivable. Pro-
gressive latent TB in HIV/AIDS patients is similar to 
progressive primary TB except that Mtb infection, in this 
case, is established before HIV-mediated immunosup-
pression. The unrestricted growth of bacilli in affected 
tissue(s) is responsible for disease symptoms in both pro-
gressive primary and progressive latent TB.
Immune reconstitution-induced TB (IR-TB), also 
known as tuberculosis-associated immune reconstitution 
inflammatory syndrome (TB-IRIS), is a special case of 
the disease observed in HIV- and Mtb-coinfected people 
treated with anti-retroviral therapy (ART) [30]. It occurs 
in diverse manifestations, including abdominal lym-
phadenopathy, pulmonary or pericardial effusions, brain 
tuberculomas, and skeletal lesions [31]. IR-TB affects up 
to 45  % the coinfected people and poses a major chal-
lenge in the clinical management of HIV infection in 
them [32]. Interestingly, IR-TB provides unequivocal 
evidence favoring the pathological role of hyperactive 
immune response during Mtb infection.
Administration of ART in HIV-infected people reduces 
viral load, leading to a rapid increase in CD4+ T cell 
count. The presence of Mtb antigens at this stage results 
in the selective expansion of Mtb-specific CD4+ T cells 
[33, 34]. Studies have shown that both terminally-differ-
entiated and effector memory CD4+ T cells with speci-
ficity to Mtb antigens are expanded in the co-infected 
people receiving ART [35, 36]. Consistent with these 
findings, conversion from a ‘negative’ TST status to a 
‘strongly positive’ one has been observed in ART-treated 
HIV- and Mtb-coinfected people. Most importantly, it 
has been demonstrated that the co-infected people who 
develop IR-TB possess higher levels of circulating Mtb-
specific CD4+ T cells, compared with those who did not 
experience this condition [34, 37, 38]. These immunolog-
ical features in the affected individuals clearly show that 
IR-TB is driven by a hyperactive CD4+ T cell response 
against Mtb antigens.
Mechanistic insights into IR-TB have been gained with 
a recently developed mouse model [39]. In this model, 
Barber et al. mimicked human IR-TB by adoptively trans-
ferring a small number of naive CD4+ T cells into M. 
avium-infected, T cell-deficient (TCRαKO) mice. It was 
observed that donor CD4+ T cells underwent a rapid 
expansion in M. avium-infected TCRαKO mice and 
led to the failure of lung function, wasting and eventual 
death. The authors further demonstrated that the ability 
to cause lung pathology was lost in IFN-gamma-deficient 
CD4+ T cells [39]. Thus, studies in both IR-TB patients 
and the animal model demonstrate the pathological role 
of hyperactive, IFN-gamma-producing CD4+ T cells dur-
ing Mtb infection.
Curative effects of vitamin D and anti‑inflammatory drugs 
against TB
Vitamin D is known to possess curative effects against TB 
since a long. Low serum level of vitamin D is an impor-
tant risk factor for TB, and polymorphisms in both vita-
min D receptor (VDR) and vitamin D-binding protein 
are associated with increased TB susceptibility [40, 41]. 
When evaluated as an adjunct to standard TB therapy, 
vitamin D has resulted in accelerated sputum conversion 
and lung healing [42]. Usefulness of vitamin D against 
TB, also observed in a host of other studies, has been 
attributed to its anti-inflammatory properties [43].
Vitamin D dampens both innate and adaptive immune 
responses [43, 44]. By promoting IκB expression, it pre-
vents nuclear translocation of NF-κB and expression of 
genes involved in the inflammatory process. Vitamin D has 
also been shown to inhibit proliferation of VDR-expressing 
T cells and induction of TH1 type of immune responses 
[45]. Negative regulatory effects of vitamin D on TH1 type 
of immune response can be partly attributed to IL-10 [46, 
47]. Interestingly, metabolites of vitamin D have been 
shown to increase the number and functions of CD4+ 
FoxP3+ T regulatory cells (Tregs), which are the impor-
tant source of IL-10 [48, 49]. These effects of vitamin D on 
Tregs are highly relevant, as the latency of Mtb infection 
has been shown to be associated with increased frequency 
of Tregs in lung tissue and bronchoalveolar lavage [50, 51].
Similar to vitamin D, steroid and non-steroid anti-
inflammatory drugs are known to possess ameliorating 
properties against TB. Corticosteroids are frequently 
used as an adjunct to standard therapy for treatment 
of various forms of TB and its associated complica-
tions, including IR-TB [52, 53]. They have been shown 
to improve TB prognosis and to reduce TB-associated 
mortality [54]. Similarly, administration of ibuprofen, a 
non-steroidal anti-inflammatory drug (NSAID), has been 
shown to result in significantly reduced bacillary load 
and increased survival of C3HeB/Fej mice, which mimics 
the granulomatous response of human TB [55]. Adminis-
tration of diclofenac has also resulted in decreased num-
ber of colony-forming units (CFUs) in spleen and liver of 
Mtb-infected animals [56].
The anti-inflammatory properties of steroids and 
NSAIDS have been implicated in their beneficial effects 
against TB. NSAIDs inhibit COX-1 and COX-2, and 
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reduce biosynthesis of prostaglandins, which are involved 
in the cardinal signs of inflammation- redness, swelling 
and pain [57]. Interestingly, higher levels of prostaglan-
din E2 have been noted in sera of active TB patients, 
compared with healthy controls [58].  Corticosteroids 
suppress proinflammatory genes mainly by histone 
deacetylase-2 (HDAC2)-mediated reversal of histone 
acetylation at activated transcription complex [59]. Sup-
pression of proinflammatory cytokines has been shown 
to be responsible for beneficial effects of prednisone 
against IR-TB [60].
The beneficial of vitamin D and other anti-inflamma-
tory agents against TB shows that controlling the host 
immune response during Mtb infection results in the 
increased resistance to active disease or in its better 
prognosis. Therefore, the pathological role of hyperac-
tive immune response in adult pulmonary TB in immu-
nocompetent hosts is corroborated by the curative effects 
of vitamin D and other anti-inflammatory agents against 
this disease.
Heterogeneity of tuberculosis
Our understanding of TB immunopathology has been 
complicated largely by the heterogeneity of this dis-
ease [5]. Latent TB and active TB are two major out-
comes of Mtb infection in humans. Active TB further 
manifests itself in different forms including primary TB 
in young children, disseminated TB in AIDS patients, 
reactivated TB in immunocompetent adults, and IR-TB 
in HIV-infected people receiving ART [5]. Heterogene-
ity of active TB is also observed in affected organs. TB 
in immunocompetent adults primarily affects lung tissue, 
whereas in young children and immunocompromised 
people, it frequently occurs in extrapulmonary form [61]. 
Different presentations of TB are the outcomes of the 
specific interaction between host immune response and 
Mtb.
The immune response against Mtb could be hypoac-
tive, balanced or hyperactive. Upon initial exposure to 
Mtb, immunocompetent adults mount a balanced anti-
mycobacterial immune response, resulting in contain-
ment of bacilli in lung granulomas and protection against 
active disease [62]. Depending on host immunoregula-
tory factors and/or exposure to external agents, the anti-
mycobacterial response could diminish or aggravate. In 
latently infected people destined to develop active TB, 
antimycobacterial immunity intensifies with time and 
after crossing a threshold, leads to the immunopathol-
ogy. As discussed above, similar aggravation of anti-
Mtb immune response also takes place in AIDS patients 
receiving ART.
The primary, disseminated and severe nature of TB in 
young children demonstrates the incompetence of their 
immune system to contain the bacilli. Interestingly, it 
has been observed that younger is a child, higher is the 
risk of TB. This pattern of disease occurrence in children 
suggests that resistance to TB develops with age (till ado-
lescence) [63]. Although the exact nature of immune-
incompetence in young children remains unclear, the 
protective efficacy of BCG against childhood TB indi-
cates the lack of effective T cell-mediated immunity 
in them [64]. A role of DCs has also been implicated in 
the inability of young children to mount an effective T 
cell response against Mtb [64]. Similar to TB in young 
children, various forms of immune-deficiencies such 
as inherited IFN-gamma deficiency and HIV-mediated 
immunosuppression also result in the extrapulmonary 
and/or disseminated TB.
It is noteworthy that outcome of the interaction 
between immune system and Mtb is shaped by multi-
ple host factors, including age, diet, body mass index, 
genetic makeup, other chronic diseases or co-infections 
and exposure to environmental mycobacteria [65]. Multi-
factorial influence on the outcome of Mtb infection may 
sometimes defy the generalizations in TB immunopa-
thology. Owing to the unrestricted growth of the bacilli 
in immunodeficient hosts, Mtb infection in a certain pro-
portion of these people can result in the pulmonary dis-
ease [66]. Alternatively, a proportion of extrapulmonary 
TB cases could be attributed to hyperactive antimycobac-
terial immune response.
Conclusion and future perspectives
The above evidence establishes that a hyperactive anti-
mycobacterial immune response, characterized by 
heightened CD4+ T cell activity and IFN-gamma levels, 
is to blame for the pathogenesis of adult pulmonary TB 
in immunocompetent hosts. This evidence is provided by 
both observational and experimental studies on human 
subjects and contradicts the commonly held view that 
weakening of immune system leads to reactivation of 
latent Mtb infection into the active disease. Although the 
risk of TB is increased with the weakening of immune 
system, TB affecting the immunocompromised hosts 
is different from that occurring in immunocompetent 
adults. In immunocompromised hosts and young chil-
dren, uncontrolled growth of the bacilli leads to the dis-
ease development, whereas in immunocompetent adults, 
immune system-mediated damage to lung tissue is to 
blame for the TB pathology. Different mechanisms of dis-
ease development are responsible for the heterogeneity 
of TB, which is being appreciated by an increasing num-
ber of researchers.
The view presented in this manuscript has a direct 
bearing on the course of TB vaccine development 
programs. Owing to the different mechanisms of 
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pathogenesis, different vaccination approaches are 
required against different forms of TB. The antimycobac-
terial immunity needs to be boosted in young children 
and tamed in the immunocompetent adults. Unfortu-
nately, the vaccinologists had been trying to boost the 
anti-Mtb immune response, without taking into consid-
eration the heterogeneity of TB and its mechanisms of 
pathogenesis. Although such vaccines could be effective 
in the young children, as in the case of BCG, they are des-
tined to fail in the immunocompetent adults.
Conclusively, if we wish to save another 100  years, 
billions of dollars, and most importantly, the millions 
of lives, it is high time to change our perspective of TB 
immunopathology. It is time to appreciate that TB is a 
heterogeneous disease and that different vaccination 
approaches are required to control its different forms. 
For TB continues to be a major public health threat 
with its drug-resistant form spreading at an alarmingly 
high rate, the onus of controlling the crisis lies with the 
immunologists.
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